Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks

Sustained Improvement ◽

26839 Dupilumab with topical corticosteroids results in rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across all anatomic regions over 52 weeks

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.489 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB118

Author(s):

Andrew Blauvelt ◽

Marjolein de Bruin-Weller ◽

Melinda Gooderham ◽

David M. Pariser ◽

Eric L. Simpson ◽

...

Keyword(s):

Atopic Dermatitis ◽

Sustained Improvement ◽

15285 Dupilumab with concomitant topical corticosteroids promotes rapid and sustained improvement in clinical signs in patients with moderate to severe atopic dermatitis: LIBERTY AD CHRONOS trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.671 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB146

Author(s):

Andrew Blauvelt ◽

Thomas Bieber ◽

Jamie Weisman ◽

Zhen Chen ◽

Brad Shumel ◽

...

Keyword(s):

Atopic Dermatitis ◽

Clinical Signs ◽

Sustained Improvement ◽

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

JAMA Dermatology ◽

10.1001/jamadermatol.2020.3260 ◽

2020 ◽

Vol 156 (12) ◽

pp. 1333 ◽

Cited By ~ 2

Author(s):

Kristian Reich ◽

Kenji Kabashima ◽

Ketty Peris ◽

Jonathan I. Silverberg ◽

Lawrence F. Eichenfield ◽

...

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety ◽

Low basal serum cortisol in patients with severe atopic dermatitis: potent topical corticosteroids wrongfully accused

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(08)70710-x ◽

2008 ◽

Vol 2008 ◽

pp. 56-57

Author(s):

B.H. Thiers

Keyword(s):

Atopic Dermatitis ◽

Serum Cortisol ◽

Topical Corticosteroids ◽

Basal Serum

Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials

Journal of Dermatological Treatment ◽

10.1080/09546634.2020.1750550 ◽

2020 ◽

pp. 1-12 ◽

Cited By ~ 1

Author(s):

S. Barbarot ◽

A. Wollenberg ◽

J. I. Silverberg ◽

M. Deleuran ◽

G. Pellacani ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Sustained Improvement

Use of Topical Corticosteroids with Tralokinumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.99 ◽

2020 ◽

Vol 4 (6) ◽

pp. s99

Author(s):

Jonathan Silverberg ◽

Andrew Pink ◽

Christina Olsen ◽

Stephan Weidinger

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Abstract not available.

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)

SSRN Electronic Journal ◽

10.2139/ssrn.3748383 ◽

2020 ◽

Author(s):

Kristian Reich ◽

Henrique D. Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Phase 3 ◽

Pivotal Phase ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials

Journal of Dermatological Treatment ◽

10.1080/09546634.2020.1839008 ◽

2020 ◽

pp. 1-10

Author(s):

K. Reich ◽

A. M. DeLozier ◽

F. P. Nunes ◽

J. P. Thyssen ◽

L. F. Eichenfield ◽

...

Keyword(s):

Atopic Dermatitis ◽

Patient Reported Outcomes ◽

Phase Iii ◽

Inadequate Response ◽

Topical Corticosteroids ◽

Patient Reported ◽

Phase Iii Trials

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial

British Journal of Dermatology ◽

10.1111/bjd.19573 ◽

2020 ◽

Cited By ~ 2

Author(s):

J.I. Silverberg ◽

D. Toth ◽

T. Bieber ◽

A.F. Alexis ◽

B.E. Elewski ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase Iii ◽

Double Blind ◽

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(17)31191-1 ◽

2017 ◽

Vol 389 (10086) ◽

pp. 2287-2303 ◽

Cited By ~ 364

Author(s):

Andrew Blauvelt ◽

Marjolein de Bruin-Weller ◽

Melinda Gooderham ◽

Jennifer C Cather ◽

Jamie Weisman ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded ◽

Term Management